These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 32622363)

  • 1. The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis.
    Yang Y; Du N; Xie L; Jiang J; Mo J; Hong J; Mao D; Ng DM; Shi H
    World J Surg Oncol; 2020 Jul; 18(1):151. PubMed ID: 32622363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials.
    Shao F; Liu J; Duan Y; Li L; Liu L; Zhang C; He S
    Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32096544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis.
    Cheng H; Yang J; Liu H; Xiang Y
    Arch Gynecol Obstet; 2021 Aug; 304(2):285-296. PubMed ID: 34021367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnitude of benefit of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for malignant tumor: A meta-analysis.
    Gu L; Du N; Jin Q; Li S; Xie L; Mo J; Shen Z; Mao D; Ji J; Khadaroo PA; Chen B
    Crit Rev Oncol Hematol; 2020 Mar; 147():102888. PubMed ID: 32018126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of PARP inhibitors in patients with BRCA-mutated advanced breast cancer: A meta-analysis and systematic review.
    Sun X; Wang X; Zhang J; Zhao Z; Feng X; Liu L; Ma Z
    Breast; 2021 Dec; 60():26-34. PubMed ID: 34455227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of PARP inhibitors in homologous recombination proficient ovarian cancer: meta-analysis.
    Skelin M; Šarčević D; Lešin Gaćina D; Mucalo I; Dilber I; Javor E
    J Chemother; 2023 Apr; 35(2):150-157. PubMed ID: 35550005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis.
    Li Y
    J Obstet Gynaecol; 2023 Dec; 43(1):2171282. PubMed ID: 36729640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
    Papa A; Caruso D; Strudel M; Tomao S; Tomao F
    J Transl Med; 2016 Sep; 14():267. PubMed ID: 27634150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: a meta-analysis.
    Lin Q; Liu W; Xu S; Shang H; Li J; Guo Y; Tong J
    BJOG; 2021 Feb; 128(3):485-493. PubMed ID: 32654312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis.
    Gulia S; Kannan S; Ghosh J; Rath S; Maheshwari A; Gupta S
    ESMO Open; 2022 Oct; 7(5):100558. PubMed ID: 36007449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of poly (adenosine diphosphate[ADP]-ribose) polymerase expression and prognosis in ovarian cancer: A systematic review and meta-analysis.
    Zhang J; Wei Z; Zhang Z
    J Gynecol Obstet Hum Reprod; 2022 Apr; 51(4):102344. PubMed ID: 35218983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis.
    Bao Z; Cao C; Geng X; Tian B; Wu Y; Zhang C; Chen Z; Li W; Shen H; Ying S
    Oncotarget; 2016 Feb; 7(7):7629-39. PubMed ID: 26399274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of poly-(ADP-ribose) polymerase (PARP)-inhibitors for the maintenance treatment after responding to first- and second-line chemotherapy in advanced ovarian cancer.
    Giuliani J; Mantoan B; Ferrario L; Candela MV; Aprile G
    J Oncol Pharm Pract; 2023 Mar; 29(2):457-464. PubMed ID: 36344039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer.
    Huang XZ; Jia H; Xiao Q; Li RZ; Wang XS; Yin HY; Zhou X
    Front Oncol; 2020; 10():958. PubMed ID: 32612955
    [No Abstract]   [Full Text] [Related]  

  • 16. Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas.
    Yi T; Feng Y; Sundaram R; Tie Y; Zheng H; Qian Y; You D; Yi T; Wang P; Zhao X
    Int J Cancer; 2019 Sep; 145(5):1209-1220. PubMed ID: 30666631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials.
    Hao J; Liu Y; Zhang T; He J; Zhao H; An R; Xue Y
    Crit Rev Oncol Hematol; 2021 Jan; 157():103145. PubMed ID: 33254040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP inhibitors in ovarian cancer.
    Ledermann JA
    Ann Oncol; 2016 Apr; 27 Suppl 1():i40-i44. PubMed ID: 27141070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of PARP Inhibitors as Maintenance Treatment on Restricted Mean Survival Time in Platinum-Sensitive Recurrent Ovarian Cancer: A Systematic Review and Meta-analysis.
    Kaneko M
    Ann Pharmacother; 2022 Jan; 56(1):27-34. PubMed ID: 33926263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
    Swisher EM; Lin KK; Oza AM; Scott CL; Giordano H; Sun J; Konecny GE; Coleman RL; Tinker AV; O'Malley DM; Kristeleit RS; Ma L; Bell-McGuinn KM; Brenton JD; Cragun JM; Oaknin A; Ray-Coquard I; Harrell MI; Mann E; Kaufmann SH; Floquet A; Leary A; Harding TC; Goble S; Maloney L; Isaacson J; Allen AR; Rolfe L; Yelensky R; Raponi M; McNeish IA
    Lancet Oncol; 2017 Jan; 18(1):75-87. PubMed ID: 27908594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.